In conclusion, based on our findings in the NSCLC cell models and the two independent patient cohorts, targeting cancer progression through DCA treatment, represents a promising strategy to increase the therapeutic effects initiated by conventional treatment like EGFR TKI and ionizing radiation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.